277 related articles for article (PubMed ID: 35780396)
21. Expressions of m6A RNA methylation regulators and their clinical predictive value in cervical squamous cell carcinoma and endometrial adenocarcinoma.
Wu H; Dong H; Fu Y; Tang Y; Dai M; Chen Y; Wang G; Wu Y
Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):270-278. PubMed ID: 33006785
[TBL] [Abstract][Full Text] [Related]
22. Genomic and transcriptomic alterations in m6A regulatory genes are associated with tumorigenesis and poor prognosis in head and neck squamous cell carcinoma.
Paramasivam A; George R; Priyadharsini JV
Am J Cancer Res; 2021; 11(7):3688-3697. PubMed ID: 34354868
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
Front Immunol; 2022; 13():976107. PubMed ID: 36091006
[TBL] [Abstract][Full Text] [Related]
24. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
25. The effect of N6-methyladenosine (m6A) factors on the development of acute respiratory distress syndrome in the mouse model.
Fei L; Sun G; Sun J; Wu D
Bioengineered; 2022 Mar; 13(3):7622-7634. PubMed ID: 35263199
[TBL] [Abstract][Full Text] [Related]
26. NME6 as a potential biomarker and therapeutic target involved in immune infiltration for lung adenocarcinoma.
Luo L; Li Y; Zhang L; Yang L
Technol Health Care; 2024 Feb; ():. PubMed ID: 38517815
[TBL] [Abstract][Full Text] [Related]
27. Constructing and validating of m6a-related genes prognostic signature for stomach adenocarcinoma and immune infiltration: Potential biomarkers for predicting the overall survival.
Yang J; Wu Z; Wu X; Chen S; Xia X; Zeng J
Front Oncol; 2022; 12():1050288. PubMed ID: 36620557
[TBL] [Abstract][Full Text] [Related]
28. Exploration of the potential roles of m6A regulators in the uterus in pregnancy and infertility.
Zhao S; Lu J; Chen Y; Wang Z; Cao J; Dong Y
J Reprod Immunol; 2021 Aug; 146():103341. PubMed ID: 34116483
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Analysis of N6-Methyladenosine (m6A) Writers, Erasers, and Readers in Cervical Cancer.
Condic M; Ralser DJ; Klümper N; Ellinger J; Qureischi M; Egger EK; Kristiansen G; Mustea A; Thiesler T
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806168
[TBL] [Abstract][Full Text] [Related]
30. Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
Liu Y; Li G; Yang Y; Lu Z; Wang T; Wang X; Liu J
Front Genet; 2021; 12():752025. PubMed ID: 35046996
[No Abstract] [Full Text] [Related]
31. Changes of N6-methyladenosine modulators promote breast cancer progression.
Wu L; Wu D; Ning J; Liu W; Zhang D
BMC Cancer; 2019 Apr; 19(1):326. PubMed ID: 30953473
[TBL] [Abstract][Full Text] [Related]
32. Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinoma.
Kong F; Wang K; Wang L
Discov Oncol; 2022 Nov; 13(1):131. PubMed ID: 36434140
[TBL] [Abstract][Full Text] [Related]
33. IGF2BP2 promotes pancreatic carcinoma progression by enhancing the stability of B3GNT6 mRNA via m6A methylation.
Cao P; Wu Y; Sun D; Zhang W; Qiu J; Tang Z; Xue X; Qin L
Cancer Med; 2023 Feb; 12(4):4405-4420. PubMed ID: 35908253
[TBL] [Abstract][Full Text] [Related]
34. N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma.
Xu H; Yin L; Xu Q; Xiang J; Xu R
Cancer Cell Int; 2022 May; 22(1):199. PubMed ID: 35606813
[TBL] [Abstract][Full Text] [Related]
35. m6A Regulators in Human Adipose Tissue - Depot-Specificity and Correlation With Obesity.
Rønningen T; Dahl MB; Valderhaug TG; Cayir A; Keller M; Tönjes A; Blüher M; Böttcher Y
Front Endocrinol (Lausanne); 2021; 12():778875. PubMed ID: 34950106
[TBL] [Abstract][Full Text] [Related]
36. Genetic alterations and functional networks of m6A RNA methylation regulators in pancreatic cancer based on data mining.
Zeng J; Zhang H; Tan Y; Wang Z; Li Y; Yang X
J Transl Med; 2021 Jul; 19(1):323. PubMed ID: 34330301
[TBL] [Abstract][Full Text] [Related]
37. Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer.
Xu LC; Pan JX; Pan HD
Cancer Manag Res; 2020; 12():5385-5394. PubMed ID: 32753956
[TBL] [Abstract][Full Text] [Related]
38. Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers.
Li R; Yin YH; Ji XL; Liu X; Li JP; Qu YQ
Front Mol Biosci; 2021; 8():644620. PubMed ID: 34150845
[TBL] [Abstract][Full Text] [Related]
39. Gene Alterations of N6-Methyladenosine (m
Zhang Q; Cai Y; Kurbatov V; Khan SA; Lu L; Zhang Y; Johnson CH
Biomed Res Int; 2020; 2020():8826456. PubMed ID: 33415160
[TBL] [Abstract][Full Text] [Related]
40. A Novel Signature Based on m6A RNA Methylation Regulators Reveals Distinct Prognostic Subgroups and Associates with Tumor Immunity of Patients with Pancreatic Neuroendocrine Neoplasms.
Chen X; Mo S; Zong L; Yu S; Lu Z; Chen J
Neuroendocrinology; 2022; 112(12):1187-1199. PubMed ID: 35609514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
